AC262,536 Solution 10mg/ml – 50ml
| Application | Selective Androgen Receptor Modulator (SARM) |
| Concentration | 1% (10mg/ml) |
| Composition | 99% PEG400, 1% AC-262,536 (>99% purity) |
| CAS | 870888-46-3 |
| Molar Mass | 278.35 g/mol |
| Synonyms | AC262536, AC-262,536 |
| Storage | Minimize open air exposure, store in a cool dry place |
| Terms | For laboratory research use only. Not for human or animal consumption. |
What Is AC262,536?
AC262,536 is a non-steroidal selective androgen receptor modulator (SARM) developed by Acadia Pharmaceuticals. It is characterized as a partial agonist at the androgen receptor with a uniquely differentiated tissue selectivity profile — demonstrating approximately 66% of the anabolic potency of testosterone in levator ani assays, while exhibiting only 27% of testosterone’s androgenic activity in prostate tissue. This anabolic-to-androgenic ratio of approximately 2.4:1 makes it an intermediate-selectivity SARM, falling between mild partial agonists like Ostarine and more potent compounds in the SARM spectrum.
AC262,536 has attracted particular interest in Alzheimer’s disease research after studies demonstrated that it could restore spatial memory in Alzheimer’s transgenic mice. Unlike most SARMs, which are primarily studied for musculoskeletal endpoints, AC262,536 has a neurological research dimension that makes it valuable in CNS studies examining androgen receptor signaling in the brain.
Mechanism of Action
AC262,536 binds the androgen receptor and acts as a tissue-selective partial agonist. In muscle and bone, it activates AR-mediated anabolic gene programs with moderate potency. In the CNS, AR activation in hippocampal neurons appears to enhance memory consolidation processes. Its partial agonist character limits receptor activation compared to full agonists, translating to less HPG axis suppression and more attenuated androgenic effects in prostate tissue.
Research Applications
- Muscle and bone anabolism: Moderate-potency SARM for anabolic endpoints with intermediate tissue selectivity.
- Alzheimer’s disease: Restored spatial memory in APPswe/PS1ΔE9 transgenic mouse models — one of the only SARMs with published CNS/memory data.
- Comparative SARM pharmacology: Bridges the selectivity gap between weak partial agonists and high-potency full agonists in panel studies.
- Neuroprotection: CNS androgen receptor activation in hippocampal memory circuits.
Related Research Compounds
AC262,536 occupies a unique niche combining moderate SARM anabolism with CNS research relevance. In comparative SARM panels, it sits between Ostarine and Andarine (S4). For dual CNS/anabolic research designs, it may be combined with MK-677 (which also has neuroprotective research relevance). For pure CNS comparators, see Noopept and NSI-189.
For laboratory research use only. Not for human or animal consumption.














Reviews
There are no reviews yet.